Bradykinin B2 receptor as a potential therapeutic target

Drug News and Perspectives

Volumn 13, Issue 4, 2000, Pages 213-225

  Heitsch, H ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[4 [4 (AMINOIMINOMETHYL)BENZOYL] 1 PIPERAZINYL]CARBONYL] 1 [2,4 DICHLORO 3 [(2,4 DIMETHYL 8 QUINOLINYL)OXYMETHYL]PHENYLSULFONYL]PYRROLIDINE; 3 (6 ACETAMIDO 3 PYRIDYL) N [N [2,4 DICHLORO 3 [(2 METHYL 8 QUINOLINYL)OXYMETHYL]PHENYL] N METHYLAMINOCARBONYLMETHYL]ACRYLAMIDE; 3 BROMO 8 [2,6 DICHLORO 3 [N [4 (N,N DIMETHYLCARBAMOYL)CINNAMIDOACETYL] N METHYLAMINO]BENZYLOXY] 2 METHYLIMIDAZO[1,2 A]PYRIDINE; 8 [2,6 DICHLORO 3 [N [4 (N METHYLCARBAMOYL)CINNAMAMIDOACETYL] N METHYLAMINO]BENZYLOXY] 2 METHYL 4 (2 PYRIDYLMETHOXY)QUINOLINE; AUTACOID; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; BRADYZIDE; CYTOKINE; DELTIBANT; DEXTRO ARGINYLBRADYKININ[3 HYDROXYPROLINE 7 DEXTRO PHENYLALANINE]; ICATIBANT; IMIDAZO[1,2 A]PYRIDINE DERIVATIVE; JMV 1116; KININ; LEUKOTRIENE; NITRIC OXIDE; NPC 18884; PROSTAGLANDIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ASTHMA; CANCER; CARDIOVASCULAR DISEASE; DRUG TARGETING; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEPATORENAL SYNDROME; HYPERTENSION; INFECTION; INFLAMMATORY DISEASE; KALLIKREIN KININ SYSTEM; PAIN; PATHOPHYSIOLOGY; RECEPTOR BLOCKING; REVIEW; SEPTIC SHOCK; TISSUE INJURY; ULCERATIVE COLITIS;

EID: 0033852880     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (127)

1. Bioregulation of kinins: Kallikreins, kininogens, and kininases
2. Pharmacology of bradykinin and related kinins
3. Metabolism of bradykinin and bradykinin analogs
4. Kinin receptor subtypes
5. Bradykinin receptors
6. Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor
7. 1 receptor
8. Regulation of bradykinin action at the receptor level
9. Bradykinin receptor antagonists
10. Bradykinin receptors and their antagonists
11. Bradykinin receptor antagonists
12. Nonpeptide antagonists for kinin receptors
13. Hoe-140. 4 new potent and long acting bradykinin antagonist: In vitro studies
14. Hoe-140. A new potent and long acting bradykinin antagonist: In vivo studies
15. A new class of bradykinin antagonists: Synthesis and in vitro activity of bissuccin-imidoalkane peptide dimers
16. Kinin receptor antagonists: Unique probes in basic and clinical research
17. Novel bradykinin receptor antagonists from a structurally-directed non-peptide combinatorial library
18. Oral anti-inflammatory actions of ATC-18884, a novel bradykinin B2 receptor antagonist
19. Oral antinociception and edema inhibition produced by NPC 18884, a non-peptidic bradykinin B2 receptor antagonist
20. Design and synthesis of a novel crass of highly potent, selective and orally active nonpeptide bradykinin B2 receptor antagonists
21. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework
22. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man
23. A novel class of orally arrive non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a]pyridine moiety
24. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation
25. Novel subtype-selective nonpeptide bradykinin B2 receptor antagonists FR 167344 and FR 173657
26. An orally active, nonpeptide bradykinin B2 receptor antagonist, FR173657
27. FR 173657: A new, potent, nonpeptide kinin B2 receptor antagonist. An in vitro study
28. Effects of the non-peptide B2 antagonist FR173657 on kinin-induced smooth muscle contraction and relaxation, vasoconstriction and prostaglandin release
29. Effects of a nonpeptide bradykinin B2 receptor antagonist, FR167344, on different in vivo animal models of inflammation
30. Characterization of FR 172357, a new non-peptide bradykinin B2 receptor antagonist, in human, pig and rabbit preparations
31. LF 16.0335, a novel potent and selective nonpeptide antagonist of the human bradykinin B2 receptor
32. Novel series of o-substituted 8-quinolines and 4-benzthiazoles as potent antagonists of the bradykinin B2 receptor
33. Bradyzide, a potent non-peptide B2 bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia
34. Quinoline and benzimidazole derivatives as bradykinin antagonists
35. Nonpeptide mimic of bradykinin with long-acting properties at the bradykinin B2 receptor
36. Pharmacological characterization of the first non-peptide bradykinin B2 receptor agonist FR 190997: An in vitro study on human, rabbit and pig vascular B2 receptors
37. FR 190997, a novel bradykinin B2 agonist, expresses longer action than bradykinin in paw edema formarion and hypotensive response
38. Pharmacological characterization of RMP-7, a novel bradykinin agonist in smooth muscle
39. Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety
40. Kinin formation: Mechanism and role in inflammatory disorders
41. Pain and hyperalgesia after intradermal injection of bradykinin in humans
42. Sensory neuropeptide released by bradykinih: Mechanisms and pathophysiological implications
43. The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat
44. Kinins and pain
45. Bradykinin and asthma
46. Nasal provocation with bradykinin induces symptoms of rhinitis and sore throat
47. The kallikrein-kinin system in asthma and acute respiratory distress syndrome
48. Role of kallikrein pathway in allergic diseases
49. Suppressive effect of distinct bradykinin B2 receptor antagonists on allergen-evoked exudation and leukocyte infiltration in sensitized rats
50. Influence of a long acting bradykinin antagonist, HOE 140, on some acute inflammatory reactions in the rat
51. Effect of HOE 140, a new bradykinin receptor antagonist, on bradykinin- and platelet activating factor-induced bronchoconstriction and airway microvascular leakage in guinea pig
52. Antinociceptive activity of the bradykinin antagonist HOE 140 in rats and mouse
53. Effect of the bradykinin antagonist HOE 140 in experimental acute pancreatitis
54. Reduction by HOE 140, the B2 kinin receptor antagonist, of antigen-induced nasal blockade
55. Additive effects of the bradykinin antagonist, NPC 17761, and a leumedin, APC 15669, on survival in animal models of sepsis
56. CP-0127, a novel bradykinin antagonist, increases survival in rat and rabbit models of endotoxic shock
57. Beneficial actions of CP-0127, a novel bradykinin receptor antagonist, in murine-traumatic shock
58. Efficacy and safety of HOE 140 (a bradykinin antagonist) in patients with mild-to-moderate seasonal allergic rhinitis
59. Efficacy and tolerability of icatibant (HOE 140) in patients with moderately severe chronic bronchial asthma
60. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127): Results of a randomized, doable-blind, placebo-controlled trial
61. Traumatic brain contusions: A clinical role for the kinin antagonist CP-0127
62. The bradykinin B2 receptor antagonist icatibant (HOE 140) corrects avid Na+ retention in rats with CC14-induced liver cirrhosis: Possible role of enhanced microvascular leakage
63. Potent, long-acting bradykinin antagonists for a wide range of applications
64. Dimers of bradykinin and substance P antagonists as poteatial anti-cancer drugs
65. Use of bradykinin antagonists for the treatment of viral diseases
66. Use of kinin antagonists for preparing a pharmaceutical composition for treating bacterial infections
67. Effect of icatibant, a bradykinin B2 receptor antagonist, on the development of experimental ulcerative colitis in mice
68. Amyloid β-(1-40) stimulates cyclic GAP production via release of kinins in primary cultured endothelial cells
69. Contribution of kinins to the cardiovascular actions of angiotensin converting enzyme inhibitors
70. Pharmacology and cardiovascular implications of the kinin-kallikrein system
71. Receptor antagonists of bradykinin: A new tool to study the cardiovascular effects of endogenous kinins
72. Interactions among ACE, kinins and NO
73. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects
74. Effects of bradykinin receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive humans
75. Effects of ramipril on mortality and morbidity on survivors of acute myocardial infarction with clinical evidence of heart failure. The investigators of the AIRE study
76. HOPE for cardiovascular disease prevention with ACE inhibitor ramipril. Heart outcomes prevention evaluation
77. Signal transduction pathways for B1 and B2 receptors in bovine pulmonary artery endothelial cells
78. Bradykinin and inositol 1,4,5-triphosphate-stimulated calcium release from intracellular stores in cultured bovine aortic endothelial cells
79. Kinins and endothelial control of vascular smooth muscle
80. Bradykinin stimulates the production of cyclic GAP via activation of B2 kinin receptors in cultured porcine aortic endothelial cells
81. Production of cGMP via activation of B1 and B2 kinin receptors in cultured bovine aortic endothelial cells
82. Direct measurement of nitric oxide release from cultured endothelial cells stimulated by bradykhffn or ramiprilat
83. The L-arginine nitric oxide pathway
84. Prostacyclin in physiology and pathophysiology
85. Bradykinin stimulates tissue plasminogen activator release in human vasculature
86. Hypotension in transgenic mice over-expressing human bradykinin B2 receptors
87. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2 receptor gene
88. Inhibition of bradykinin-induced vasodilation in the human forearm vasculature by icatibant, a B2 receptor antagonist
89. Bradykinin B2 receptors mediate the pressor and renal hemodynamic effects of intravenous bradykinin in conscious rats
90. A nonpeptide mimic of bradykinin blunts the development of hypertension in young spontaneously hypertensive rats
91. Regulation of mitogenesis by kinins in arterial smooth muscles
92. Bradykinin prevents left ventricular hypertrophy in rats
93. A specific B2 bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril
94. Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells
95. Left ventricular hypertrophy and its relation to the cardiac kinin-forming system in hypertensive and diabetic rats
96. Potent antihypertrophic effect of the bradykinin B2 receptor system on the renal vasculature
97. Role of kinins in the pathophysiology of myocardial ischaemia: In vitro and in viva studies
98. Role of endogenous bradykinin in human coronary vasomotor control
99. A comparison of the effects of locally and systemically administered kinins on coronary blood fiow and myocardial metabolism
100. Local inhibition of bradykinin degradation in ischemic hearts
101. Reduction of myocardial infarct size in rabbits by ramiprilat: Reversal by the bradykinin antagonist HOE 140
102. Beneficial effects of bradykinin on porcine ischemic myocardiurn
103. Attenuation of epinephrine-induced dysrhythmias by bradykinin: Role for nitric oxide and prostaglandins
104. Role of kallikrein-kinin system in reduction of myocardial infarct size in rats
105. Local intracoronary infusion of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anesthetized dogs
106. Attenuation of reperfusion arrhythmias by selective inhibition of angiotensin-converting enzyme/kininase II in the ischemic zone: Mediated by endogenous bradykinin?
107. Effect of bradykinin and its antagonists on survival time after coronary artery occlusion in rats
108. Upregutation of the cardiac B2 receptors after myocardial infarction
109. Protection of heart by ischemic preconditioning; mechanisms and possible pharmacological exploitations
110. Does ischemic preconditioning occur in patients?
111. Role of bradykinin in the protection of ischemic preconditioning in rabbit hearts
112. Signal transduction in ischemic preconditioning
113. Mitochondria: A new target for K+ channel openers?
114. Role of bradykinin in myocardial preconditioning
115. Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning - A brief review of evidence
116. Role of bradykinin in cardiac functional properties after global ischemia-reperfusion in rat hearts
117. Role of kinins in the endothelial protective effect of ischemic preconditioning
118. Role of kinins in the cardioprotective effect of preconditioning: Study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats
119. Bradykinin-induced preconditioning in patients undergoing coronary angioplasty
120. Angiotensin-converting enzyme inhibitors and coronary artery disease
121. The kallikrein-kinin system in post-myocardial infarction cardiac remodeling
122. Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice
123. Experimental studies on the influence of the kallikrein-kinin system on glucose utilization
124. Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin
125. Bradykinin potentiates insulin-stimulated glucose uptake and enhances insulin signal through the bradykinin B2 receptor in dog skeletal muscle and rat L6 myoblasts
126. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor
127. Insulin sensitivity, clearance and release in kininogen-deficient rats